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94 Poster Session Ifrom umbilical cord blood (CB) is unknown.We performed in vitro
and in vivo studies comparing bone marrow (BM)-derived CD1331
cells from chronic coronary artery patients enrolled in the Safety
And Efficacy Of Autologous Intracoronary Stem Cell Injections
In Total Coronary Artery Occlusions (SEACOAST). Patient- and
control-derived blood cells mononuclear cells (MNC) from periph-
eral blood (PB) and BM were tested for endothelial cell colony for-
mation (CFU-EC), and tested functionally by in vitromigration and
the ability to augment blood flow in a mouse hindlimb ischemia
model. Patient-derived BM CD1331 cells, isolated with the Clini-
MACS device (84 6 7% purity and 76 6 7% viability (7–7AAD),
contained non-CD1331 cells following selection: \ 5% CD3,
CD3neg/CD56, CD19 (immature/mature), CD14, or CD71 cells,
5% CD611 cells, and 8% CD131 SSChigh cells. BM and PB-de-
rived MNC from patients produced less colonies compared to
healthy controls and CB: CB, 35.8 6 41.7, control PB, 79.6 6 49;
control BM, 24.8 6 13.7; patient PB, 6.9 6 9.3 and BM, 0.86 6
0.83. Transmigration of selected CD1331 cells to the stromal
cell-derived factor-1 (SDF-1) chemokine was performed. Transmi-
gration of control and patient-derived CD1331 cells in response to
200 ng/ml SDF-1 was 64.5 6 23.1% and 9.3 6 3.8%. Control or
patient-derived cells or media was injected (intracardiac) into
NOD/SCID mice after femoral artery ligation. Doppler flow mea-
surements comparing ischemic/healthy limb perfusion ratios at 28
days were higher in mice receiving control CD1331 cells (0.51 6
0.06) compared to those receiving media control (0.37 6 0.03, p
\ 0.05). No improvement of receiving patient-derived BM
CD1331 cells (0.46 6 0.04) or PB MNC (0.37 6 0.08) was ob-
served (p5 0.07, p5 0.94, respectively). Diminished biological po-
tency of chronic ischemic patient-derived cells was observed in in
vitro and in vivo studies when compared to cord blood and healthy
control-derived cells.254
AMD3100 MOBILIZES A MORE PRIMITIVE HEMATOPOIETIC PROGENI-
TOR SUBSET FROM HUMAN MARROW
Wagner, W.1,2, Fru¨hauf, S.1, Callandra, G.3, Ho, A.D.1. 1University of
Heidelberg, Heidelberg, Germany; 2University of Heidelberg, Germany;
3Genzyme, Boston, Germany.
Our group demonstrated the significance of specific adhesion
molecules and of junction formation between human hematopoietic
progenitor cells (HPC) and human mesenchymal stromal cells
(MSC) in maintaining stemness. For example, CXCR4/SDF-1a as
well as b1-integrins were shown to be major mediators of stem
cell homing and adhesion to the niche. AMD3100, a novel
CXCR4 antagonist, inhibits efficiently the binding of CXCR4 to
SDF1a and has been shown to induce a rapid release of HPC
from the bone marrow to peripheral blood.
We have monitored migration and cell-cell adhesion of HPC to-
wards MSC under the influence of SDF-1a, AMD3100 and the ap-
propriate controls. Simultaneously we participated in amulti-center
trial sponsored by Anormed (Vancouver, Canada, subsequently
Genzyme, Boston) in patients who were poor mobilizers. Patients
with multiple myeloma and non-Hodgkin-lymphoma were treated
with AMD3100 administered 12 hours before apheresis and follow-
ing 4 days of granulocyte colony-stimulating factor (G-CSF),. This
offered the opportunity to measure the numbers, the phenotypes
and function of the CD341 cells mobilized by AMD3100 1 G-
CSF versus those by G-CSF alone in the same subjects.
The primitive subsets (CD341/CD38-) were significantly more
adherent to MSC than the committed HPC (CD341/CD381).
Functionally LTC-IC were found exclusively among the HPC ad-
herent to MSC. There was a significant reduction in adhesion of
HPC to MSC upon in vitro treatment with AMD3100 (32% 6
11%; P5 7 10–5) or with SDF-1a (55%6 13%; P5 .014), versus
controls (74%6 10%). Analysis ofHPCmobilized by AMD31001
G-CSF in the patients (n 5 7) indicated that HPC are completely
different from those mobilized with G-CSF. The most significant
findings were (1) an overall increase in the concentration of
CD341 cells after administration of AMD3100 (2.8 fold with
a range from 1.1X to 6.9X), and (2) an increase in the primitive sub-
set CD341/CD38- cells versus stimulation with G-CSF alone. Themedian increase in CD341/CD38- was 3.6 fold with a range of
1.3X to 5.7X. Parallel to this increase, functional assay also indi-
cated that the CD341 cells mobilized by G-CSF1AMD3100
were more potent, LTC-IC being 1.4 fold with a range from 1.1X
to 2.6X as compared to that after G-CSF alone. Thus a precise un-
derstanding of the mechanisms behind homing and adhesion of
HPC to the cellular niche has led to the development of a novel
agent for the efficient mobilization of more potent HPC.255
RESCUEMOBILIZATION OF HEMATOPOIETIC PROGENITOR CELLSWITH
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Background: The failure rate for hematopoietic progenitor cell
mobilization varies from 5% inMultipleMyeloma pts to 30% in pts
with non-Hodgkin lymphoma and Hodgkin lymphoma.Methods:
We report the results of a single center experience with AMD3100
(plerixafor)1G-CSF as a rescue progenitor cell mobilization in pa-
tients who had failed a prior mobilization. Mobilization failure was
defined as inability to collect$ 2 106 CD341 cells/kg or inability
to achieve a peripheral bloodCD341 cells/ml of$10 and not apher-
esed. Rescue mobilization consisted of G-CSF at 10 mcg/kg/day sq
on days 1–4 plus AMD3100 at 240 mcg/kg/day sq on the evening of
day 4 and continued until the goal of 5  106 CD341 cells/kg was
reached or a maximum of 7 aphereses. Apheresis began on day 5 re-
gardless of the peripheral bloodCD341 cells/ml.Results:Twenty-
nine pts participated in this compassionate use protocol. Demo-
graphics were 11 females and 18 males; 14 pts had NHL, 10 MM,
3 AL amyloidosis and 2 HD. The median age was 63 years (range
37–73). Prior mobilization was G-CSF alone in 25 pts, G-CSF 1
GM-CSF in 2 and chemotherapy 1 G-CSF in 2. Median time
from prior mobilization failure to AMD3100 rescue mobilization
was 0.7 months (range 0.4–33). The median peripheral blood
CD341 cells/ml value prior to AMD3100 was 4.8 (range 0–18.2)
and 12 hours post AMD3100 was 12.4 (range 2–49.5), a 2.7 fold in-
crease (range 0.5–7.4). The median number of CD341 cells har-
vested was 4.71  106 CD341 cells/kg (range 0.25–9.37). Seven
pts (24%) failed to achieve a minimum of $2  106 CD341
cells/kg. Twenty-two of 29 pts (76%) successfully collected at least
2 106 CD341 cells/kg and 12 (41%) collected$ 5 106 CD341
cells/kg. Median number of aphereses in the successful pts was 5
(range 2–7) and the median number of aphereses to reach 2  106
CD341 cells/kg was 2 (range 1–7). Twenty-five pts (86%) went
on to ASCT. This included 4 pts who collected # 2  106
CD341 cells/kg (1.01, 1.44, 1.5, and 1.98) and underwent bone
marrow harvest. One pt who successfully collected has not yet un-
dergone ASCT. All pts had successful engraftment; median time
to neutrophil engraftment (500/ml) was 13 days (range 11–18) and
median time to platelet engraftment (50,000/ml) was 22 days (range
16–231).Conclusion: The addition of AMD3100 to G-CSF effec-
tively mobilizes CD341 cells in themajority of pts, in whom a prior
mobilization with either growth factors or chemotherapy has failed
to mobilize sufficient cells for ASCT.256
POTENTIAL BIODOSIMETRY MARKERS OF RADIATION EXPOSURE
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Background: According to a Joint Interagency Group directed
by the Department of Defense, radiological dose assessment is im-
perative to decrease morbidity and mortality following a radiologi-
cal event. Dose assessment requires the development of rapid,
